WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 182
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 212

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 1'344  1'341  1'337  1'333  1'328  1'268  1'222  1'085 
Births 19  19  20  20  20  19  25  31 
Surviving infants 19  19  19  19  20  18  25  30 
Pop. less than 5 years 96  97  97  98  97  90  133  132 
Pop. less than 15 years 280  279  277  276  275  324  410  369 
Female 15-49 years 350  355  359  363  366  353  314  282 

Number of reported case

(Click for retrospective incidence data for Trinidad and Tobago)
Diphtheria
Japanese encephalitis
Measles 511  384 
Mumps
Pertussis 10 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 10  28 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Trinidad and Tobago)
Vaccine year result method % card seen                                                
BCG         
DTP1          93  94  87  89  89  90 
DTP3          92  92  92  90  90  90  82  26 
DTP4          75 
IPV1          67 
HepB_BD         
HepB3          92  92  92  90  90 
Hib3          92  92  92  90  90  74 
JapEnc         
MCV1          96  91  85  92  92  90  71 
MCV2          93  86  85  99*  99* 
PCV1          94  91  81 
PCV3          95  80  39 
Pol3          94  94  91  91  91  90  87  38 
Rota1         
Rota_last         
Rubella1          96  91  86  92  92 
TT2plus          14  15  14  14  14 
PAB         
VAD1         
YFV          96  89  85  95  95 
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Trinidad and Tobago)
DTP1 93  94  97  96  96  90  94  51 
DTP3 92  92  92  90  90  90  82  26 
HepB3 92  92  92  90  90 
HepB_BD
Hib3 92  92  92  90  90  74 
MCV1 96  91  85  92  92  90  70 
MCV2 93  86  85  83  82 
PCV3 95  80  39 
Pol3 94  94  91  91  91  90  87  38 
Rota_last
YFV 96  89  85  95  95  91 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 89
From 80 to 89% 11
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 4, 6, 18 months; 4-5 years; Yes Children Allergic to Pertussis
DTwP 18 months; 4-5 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HIB 2, 4, 6 months; Yes immunosupressed
HPV >= 11 years; +2, +6 months; No females 11-45 years and males 11-26 years
HepB_Adult 10 years; +2, +6 months; Yes adolescents and adults
IPV 2, 4, 5, 18 months: 4-5 years; No immunosupressed
Influenza_Adult Yes Adults with chronic diseases
Influenza_Pediatric Yes children with chronic diseases
MMR 12 months; 4 years; Yes
MenAC >= 2 years; No mainly travellers
OPV 2, 4, 6, 18 months; 4-5 years; Yes
Pneumo_conj 2, 4, 6, >=12 months; Yes
Pneumo_ps >= 24 months; No high risk
Rabies 0, 3, 7, 14, 28-35 days; No high risk
Td +10, +20 years; Yes
Varicella >= 12 months; No at risk
YF 1, 11 years; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2016-2018  2013-2014  2012 -2013  2011-2012  2010-2011  2009-2010  2008-2009 
Nº of districts with microplans that include activities to raise immunization coverage number

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  89  89  100  89 
Nº districts with measles (MCV1) coverage >=95% number
% of districts with MCV1 coverage >=95% From 0 to 100% 67  44  33  56  56  67  44 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  No  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   95  100    100  100   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No    No     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.